Life science companies want their say in efforts to improve EU and US "regulatory compatibility"
This article was originally published in Clinica
Executive Summary
Drug and medical device companies in the EU and the US are preparing a list of issues that they want to be addressed under a transatlantic initiative aimed at reducing unnecessary regulatory barriers that exist between the two regions.